AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30736841 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel supraglottic airway device
Number of subjects: 1500
Study 30736841 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 1500
Study 28653869 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (NEMEX) program; 8-week, twice-weekly program consisting of 11 exercises with 3 to 4 levels of difficulty
Number of subjects: 23
Study 26293146 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg
Number of subjects: 105
Study 26293146 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg
Number of subjects: 105
Study 26293146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 23500230 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclacumab 20 mg/kg
Number of subjects: 544
Study 23500230 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclacumab 5 mg/kg
Number of subjects: 544
Study 23500230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study 21457056 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation counseling delivered by cell phone
Number of subjects: 40
Study 21457056 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 40
Study 18212288 — intervention group
Group type: COMPARATOR
Intervention: Gadoversetamide 0.05, 0.1, 0.2, or 0.3 mmol/kg
Number of subjects: 566
Study 18212288 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoversetamide doses > or = 0.2 mmol/kg
Number of subjects: 566
Study 17013851 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 221
Study 17013851 — intervention group
Group type: COMPARATOR
Intervention: Range-of-Motion (ROM)
Number of subjects: 221
Study 12728756 — intervention group
Group type: EXPERIMENTAL
Intervention: Group visits
Number of subjects: 120
Study 12728756 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 11303311 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticosteroids (gcs), total dose equivalent to prednisone 7.4 ± 8.3 g
Number of subjects: 90
Study 11303311 — intervention group
Group type: COMPARATOR
Intervention: No treatment with glucocorticosteroids (gcs)
Number of subjects: 90
Study 8619449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine 1,200 mg over a three-day period (Group I)
Number of subjects: 101
Study 8619449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine 1,800 mg over a five-day period (Group II)
Number of subjects: 101
Study 8619449 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro drug sensitivity tests
Number of subjects: 101
Study 1463951 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol plus unwrapping
Number of subjects: 52
Study 1463951 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm sponging plus unwrapping
Number of subjects: 52
Study 1463951 — intervention group
Group type: COMPARATOR
Intervention: Unwrapping alone
Number of subjects: 52
Study 1463951 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 52
Study 1463951 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm sponging
Number of subjects: 52
Study 6363434 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (DHT) 125 mg twice daily for 10 days
Number of subjects: 12
Study 31688451 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-02545920 5 mg Q12H
Number of subjects: 259
Study 31688451 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-02545920 15 mg Q12H
Number of subjects: 259
Study 31688451 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 3 mg Q12H
Number of subjects: 259
Study 31688451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 29905383 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 50 mg
Number of subjects: 192
Study 29905383 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Number of subjects: 192
Study 29905383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 27271613 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng-Huayu (FZHY) formula
Number of subjects: 0
Study 27271613 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA panel (hsa-miR-18a-5p, -326, -1182, -193b-5p)
Number of subjects: 0
Study 25358527 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH (Disabilities of the Arm, Shoulder and Hand)
Number of subjects: 153
Study 22291101 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine (ZV) (Zostavax; Merck)
Number of subjects: 22439
Study 22291101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22439
Study 22291101 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine (ZV)
Number of subjects: 22439
Study 20818269 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize after phytate reduction for 40 days
Number of subjects: 10
Study 20818269 — intervention group
Group type: COMPARATOR
Intervention: Habitual maize‐based high‐phytate diet
Number of subjects: 10
Study 17415555 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy + midazolam
Number of subjects: 80
Study 17415555 — intervention group
Group type: COMPARATOR
Intervention: Flexible cystoscopy + no midazolam
Number of subjects: 80
Study 17415555 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid cystoscopy + midazolam
Number of subjects: 80
Study 17415555 — intervention group
Group type: COMPARATOR
Intervention: Rigid cystoscopy + no midazolam
Number of subjects: 80
Study 15642565 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 0
Study 15642565 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 0
Study 11856079 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide, 6.75 g daily
Number of subjects: 57
Study 11856079 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine, 3 g daily
Number of subjects: 57
Study 9659868 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 32
Study 9659868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8134222 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (15 mg/kg per dose, 0.15 mL/kg per dose) every 6 hours for 24 hours
Number of subjects: 44
Study 8134222 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.15 mL/kg per dose) every 6 hours for 24 hours
Number of subjects: 44
Study 8134222 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen and Placebo (both groups)
Number of subjects: 44
Study 2504359 — intervention group
Group type: EXPERIMENTAL
Intervention: Written invitations to have a smear taken
Number of subjects: 416
Study 2504359 — intervention group
Group type: EXPERIMENTAL
Intervention: Notes tagged for doctor reminders
Number of subjects: 416
Study 2504359 — intervention group
Group type: COMPARATOR
Intervention: No special intervention (Control group)
Number of subjects: 416
Study 1168110 — intervention group
Group type: EXPERIMENTAL
Intervention: Hog mucosal heparin
Number of subjects: 24
Study 1168110 — intervention group
Group type: COMPARATOR
Intervention: Beef lung heparin
Number of subjects: 24
Study 31856476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation with optic capture through a primary posterior continuous curvilinear capsulorhexis (PPC) without vitrectomy
Number of subjects: 15
Study 31856476 — intervention group
Group type: COMPARATOR
Intervention: Endocapsular IOL implantation with PPC and anterior vitrectomy
Number of subjects: 15
Study 31135550 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (enoxaparin 40 mg or dalteparin 5000 IUs daily)
Number of subjects: 637
Study 31135550 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis (various types including aspirin and warfarin)
Number of subjects: 637
Study 31135550 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic VTE
Number of subjects: 637
Study 31135550 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 637
Study 28406882 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational support (ES) group - additional polysomnography chart viewing from both diagnostic and titration nights
Number of subjects: 115
Study 28406882 — intervention group
Group type: COMPARATOR
Intervention: Standard support (SS) group - general information about OSA and PAP treatment at baseline
Number of subjects: 115
Study 25468670 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% Cypermethrin + 30% Chlorpyriphos + 15% Fenthion‐Colosso(®) FC 30
Number of subjects: 0
Study 25468670 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% Dichlorvos + 20% Chlorpyriphos‐Ectofós(®)
Number of subjects: 0
Study 25468670 — intervention group
Group type: COMPARATOR
Intervention: Field trials with naturally infected animals
Number of subjects: 0
Study 25468670 — intervention group
Group type: COMPARATOR
Intervention: Stall Tests using artificially infested cattle
Number of subjects: 0
Study 25468670 — intervention group
Group type: COMPARATOR
Intervention: Adult Immersion Tests (AIT)
Number of subjects: 0
Study 23500298 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (ECV)
Number of subjects: 321
Study 23500298 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic cardioversion (PCV)
Number of subjects: 321
Study 23500298 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 321
Study 23500298 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of ECV, PCV, or AF ablation
Number of subjects: 321
Study 23500298 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke or systemic embolism
Number of subjects: 321
Study 23500298 — intervention group
Group type: EXPERIMENTAL
Intervention: Death
Number of subjects: 321
Study 23500298 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization after cardioversion or AF ablation
Number of subjects: 321
Study 23500298 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term incidence of stroke or systemic embolism
Number of subjects: 321
Study 23500298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular death
Number of subjects: 321
Study 23500298 — intervention group
Group type: EXPERIMENTAL
Intervention: Death from all causes
Number of subjects: 321
Study 21749677 — intervention group
Group type: EXPERIMENTAL
Intervention: MDFT (Multidimensional Family Therapy)
Number of subjects: 450
Study 21749677 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 450
Study 19459997 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 60 mg extended release (XR)
Number of subjects: 1165
Study 19459997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1165
Study 16702250 — intervention group
Group type: EXPERIMENTAL
Intervention: Microstream capnography monitoring
Number of subjects: 163
Study 16702250 — intervention group
Group type: COMPARATOR
Intervention: Routine care with 2-L supplemental oxygen via nasal cannula and capnography monitoring for >60 seconds
Number of subjects: 163
Study 12669751 — intervention group
Group type: EXPERIMENTAL
Intervention: Apparent motion used to define high-level representation associated with the target.
Number of subjects: 0
Study 12669751 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial display followed by a second display with masks appearing at new locations.
Number of subjects: 0
Study 10722180 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (mean total daily dose 455 mg)
Number of subjects: 448
Study 10722180 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (mean total daily dose 8 mg)
Number of subjects: 448
Study 10722180 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 448
Study 10722180 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 448
Study 8615421 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate and valproate plus lithium
Number of subjects: 0
Study 8615421 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine and carbamazepine plus lithium
Number of subjects: 0
Study 8615421 — intervention group
Group type: COMPARATOR
Intervention: Lithium monotherapy
Number of subjects: 0
Study 1399665 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 25
Study 1399665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondependent position (right lateral)
Number of subjects: 25
Study 1399665 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependent position (left lateral)
Number of subjects: 25
Study 1399665 — intervention group
Group type: EXPERIMENTAL
Intervention: Age correlation with PaO2
Number of subjects: 25
Study 1399665 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of atelectasis correlation with change in PaO2
Number of subjects: 25
Study 4040552 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (IV, 2 mg/kg over 15 minutes, given 30 minutes before, 30 minutes after, and three hours after cisplatin)
Number of subjects: 60
Study 4040552 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine (IV, given 30 minutes before and three hours after cisplatin; placebo at 30 minutes after cisplatin)
Number of subjects: 60
Study 4040552 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of adverse reactions
Number of subjects: 60
Study 31039052 — intervention group
Group type: COMPARATOR
Intervention: Camrelizumab monotherapy (200 mg)
Number of subjects: 86
Study 31039052 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (10 mg/d, days 1 to 5) plus camrelizumab (200 mg, day 8)
Number of subjects: 86
Study 31039052 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine plus camrelizumab
Number of subjects: 86
Study 28483191 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at the Zusanli (ST-36) acupoint for 30 minutes per visit for 11 weeks
Number of subjects: 30
Study 28483191 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment (control group)
Number of subjects: 30
Study 25566730 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (NSC) 200 IU/day
Number of subjects: 90
Study 25566730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 25566730 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (NSC)
Number of subjects: 90
Study 24722500 — intervention group
Group type: EXPERIMENTAL
Intervention: Imeglimin (1,500 mg b.i.d.)
Number of subjects: 170
Study 24722500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 23102076 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% glyceryl trinitrate (GTN) ointment
Number of subjects: 210
Study 23102076 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative management (Control)
Number of subjects: 210
Study 19403710 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (plasma ferritin <12 microg/L or transferrin receptor >4.4 mg/L)
Number of subjects: 272
Study 19403710 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia (hemoglobin <120 g/L)
Number of subjects: 272
Study 19403710 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate deficiency (plasma folate <or=10 nmol/L)
Number of subjects: 272
Study 19403710 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency and anemia
Number of subjects: 272
Study 19403710 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron stores
Number of subjects: 272
Study 19403710 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of anemia among nonstudents
Number of subjects: 272
Study 19403710 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of anemia among women with previous miscarriage
Number of subjects: 272
Study 19403710 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of anemia among iron-deficient women
Number of subjects: 272
Study 19403710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean plasma ferritin concentration in adolescents (<or=19 y)
Number of subjects: 272
Study 19403710 — intervention group
Group type: EXPERIMENTAL
Intervention: Body iron stores in adolescents (<or=19 y)
Number of subjects: 272
Study 17970235 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic foods (fruits, vegetables, red wine, milk)
Number of subjects: 10
Study 17970235 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean organic diet for 14 days
Number of subjects: 10
Study 17970235 — intervention group
Group type: COMPARATOR
Intervention: Conventional foods (fruits, vegetables, red wine, milk)
Number of subjects: 10
Study 15456204 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit by a midwife from the maternity ward of the hospital
Number of subjects: 605
Study 11442213 — intervention group
Group type: COMPARATOR
Intervention: Placebo and chloroquine treatment for symptomatic malaria infection
Number of subjects: 215
Study 11442213 — intervention group
Group type: COMPARATOR
Intervention: Placebo and monthly presumptive treatment with sulfamethoxazole-pyrimethamine (SP)
Number of subjects: 215
Study 11442213 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly SP and thrice‐weekly vitamins A and C (VAC)
Number of subjects: 215
Study 9474601 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intraocular lenses (IOLs)
Number of subjects: 119
Study 9474601 — intervention group
Group type: COMPARATOR
Intervention: Polymethylmethacrylate (PMMA) intraocular lenses (IOLs)
Number of subjects: 119
Study 7664433 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg BID, n = 33)
Number of subjects: 56
Study 7664433 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 56
Study 2666040 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg acyclovir by mouth, twice daily, for 12 weeks
Number of subjects: 24
Study 2666040 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo by mouth, twice daily, for 12 weeks
Number of subjects: 24
Study 1052834 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral sinusoidal E.C.T.
Number of subjects: 66
Study 1052834 — intervention group
Group type: COMPARATOR
Intervention: Bilateral sinusoidal E.C.T.
Number of subjects: 66
Study 1052834 — intervention group
Group type: COMPARATOR
Intervention: Pulse E.C.T.
Number of subjects: 66
Study 30916007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation with caudal block
Number of subjects: 104
Study 30916007 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with caudal block
Number of subjects: 104
Study 28982380 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Who's Challenging Who?' (WCW) training intervention
Number of subjects: 236
Study 28982380 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 236
Study 25734713 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐PRF (Leukocyte‐ and platelet‐rich fibrin)
Number of subjects: 44
Study 25734713 — intervention group
Group type: COMPARATOR
Intervention: CTG (free connective tissue grafts)
Number of subjects: 44
Study 24142213 — intervention group
Group type: EXPERIMENTAL
Intervention: Calatonia technique
Number of subjects: 116
Study 24142213 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-intentional touches)
Number of subjects: 116
Study 22448476 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavir added to combined treatment
Number of subjects: 0
Study 19834767 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II hysterectomy (modified radical hysterectomy)
Number of subjects: 520
Study 19834767 — intervention group
Group type: COMPARATOR
Intervention: Class I hysterectomy (extrafascial hysterectomy)
Number of subjects: 520
Study 16317106 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter Orange (900 mg dietary supplement extract standardized to 6% synephrine)
Number of subjects: 15
Study 16317106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 14744573 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg i.v. loading dose followed by 0.5 mg i.v. infusion over 30 min)
Number of subjects: 8
Study 14744573 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study 11384023 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine (adrenaline)
Number of subjects: 10
Study 11384023 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% prilocaine with 0.03IU/ml felypressin
Number of subjects: 10
Study 8996293 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (Fragmin)
Number of subjects: 971
Study 8996293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 971
Study 8499580 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg fluvoxamine maleate
Number of subjects: 12
Study 8499580 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg fluvoxamine maleate
Number of subjects: 12
Study 8499580 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg fluvoxamine maleate
Number of subjects: 12
Study 8499580 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (all doses)
Number of subjects: 12
Study 6356306 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortin butylester (FCB) administered by inhalation through a special inhalator (Rhinolator) for three weeks
Number of subjects: 31
Study 6356306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 31751388 — intervention group
Group type: EXPERIMENTAL
Intervention: Poultry workers with multidrug resistant (MDR) E. coli
Number of subjects: 122
Study 31751388 — intervention group
Group type: EXPERIMENTAL
Intervention: Poultry workers with absence of lavatory
Number of subjects: 122
Study 31751388 — intervention group
Group type: EXPERIMENTAL
Intervention: Poultry workers with history of diarrhea in last three months
Number of subjects: 122
Study 31751388 — intervention group
Group type: EXPERIMENTAL
Intervention: Poultry workers with farm/market existence for >10 years
Number of subjects: 122
Study 31751388 — intervention group
Group type: EXPERIMENTAL
Intervention: Poultry workers controlling for age with absence of lavatory
Number of subjects: 122
Study 31751388 — intervention group
Group type: EXPERIMENTAL
Intervention: Poultry workers controlling for age with history of diarrhea
Number of subjects: 122
Study 31751388 — intervention group
Group type: EXPERIMENTAL
Intervention: Poultry workers controlling for age with work exposure >10 years
Number of subjects: 122